WHO ICTRP trial
a study of HER2-CAB-T Cell (chimeric CD3e and anti-CD3 based Bispecific T cell…
ChiCTR2100046713 · Chinese Clinical Trial Registry (ChiCTR) · Recruiting
Key facts
| Trial ID | ChiCTR2100046713 |
|---|---|
| Public title | a study of HER2-CAB-T Cell (chimeric CD3e and anti-CD3 based Bispecific T cell activator engineered T cells) for the treatment of advanced solid tumors |
| Scientific title | a Study to Evaluate the Tolerance, Safety, Pharmacokinetics and Preliminary Efficacy of HER2-Targeted CAB-T(PM3002)in Patients with Advanced Solid Tumors |
| Primary sponsor | Shanghai Tenth People's Hospital |
| Registry | Chinese Clinical Trial Registry (ChiCTR) |
| Recruitment status | Recruiting |
| Study type | Interventional study |
| Phase | 0 |
| Countries | China |
| Conditions | advanced solid tumors |
| Interventions | Dose escalation group:PM3002 injection;Dose expansion group:PM3002 injection |
| Registration date | May 27, 2021 |
| Target size | Dose escalation group:15;Dose expansion group:20 |
| Registry page | chictr.org.cn |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: